The Potential of Ameliorating COVID-19 and Sequelae From <i>Andrographis paniculata</i> via Bioinformatics

Nguyen, Hien Thi; Đỗ, Văn Mãi; Phan, Thanh T.N.; Huynh, Dung Tam Nguyen

doi:10.1177/11779322221149622

Cited by 3 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, it has anti-inflammatory and immunomodulatory properties, which help to mitigate the host inflammatory response phase associated with severe infection. The bioactive components of Andrographolide are enriched in processes associated with responses to chemical stress, cytokine-mediated signaling pathways, and inflammatory responses [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial

Prasoppokakorn,

Sriphoosanaphan,

Nalinthassanai

et al. 2024

OBM Integr Complement Med

View full text Add to dashboard Cite

Reports indicate that Andrographolide inhibits viral replication and reduces COVID-19 symptoms. This study aimed to determine Andrographolide's additional effect and safety in mild COVID-19 patients treated with favipiravir. A multicenter, open-labeled, randomized controlled trial was conducted from October 2021 to February 2022. The patients were randomized to receive a combination of Andrographolide and favipiravir or favipiravir monotherapy. The primary outcome was the occurrence rate of severe pneumonia. The secondary outcomes were symptom improvement, inflammatory biomarkers, and adverse events on days 7 and 14. 82 mild COVID-19 patients were enrolled; 43 and 39 patients received either combination therapy or favipiravir alone. Baseline characteristics were comparable. None developed severe pneumonia, requiring a mechanical ventilator. The Andrographolide group had a significant reduction of cough compared to the controlled group; 13 (30.2%) vs. 22 (56.4%), p = 0.017 on day 7 and 4 (9.3%) vs. 7 (17.9%), p = 0.025 on day 14. Moreover, the Andrographolide group had significantly lower levels of inflammatory markers on day 7, CRP (5.8 vs. 18.4 mg/L; p = 0.019) and IL-6 (2.0 vs. 21.8 pg/mL; p = 0.001) but not on day 14. Regarding safety outcomes, the Andrographolide group had significantly higher AST levels on day 7 (40.3 vs. 32.2 U/L; p = 0.030) and both AST and ALT levels on day 14 (55.3 vs. 32.0; p = 0.014 and 63.8 vs. 40.0; p = 0.022, respectively). In mild COVID-19 patients, the combination of Andrographolide and favipiravir did not demonstrate additional benefits over favipiravir alone in preventing severe pneumonia. However, Andrographolide significantly reduced cough symptoms, especially during the first week. Furthermore, despite mild transaminitis, patients treated with Andrographolide showed improvements in inflammatory markers.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial

Prasoppokakorn,

Sriphoosanaphan,

Nalinthassanai

et al. 2024

OBM Integr Complement Med

View full text Add to dashboard Cite

show abstract

Taiwan Chingguan Yihau may improve post-COVID-19 respiratory complications through PI3K/AKT, HIF-1, and TNF signaling pathways revealed by network pharmacology analysis

Huynh,

Nguyen,

Hsieh

2024

Mol Divers

View full text Add to dashboard Cite

Antiviral efficacy of Andrographis paniculata and andrographolides: A narrative review

Chidambaram

2024

Asian Pacific Journal of Tropical Biomedicine

View full text Add to dashboard Cite

The rise of emerging infectious diseases has become notably prominent due to ecological changes and mutations in pathogens. The respiratory illness outbreak caused by the COVID-19 pandemic has spread globally. Natural products contain numerous structures and biological activities, offering ample options for discovering new antiviral drugs with unique targets and mechanisms. Andrographis paniculata has been utilized in Indian Ayurvedic, Swedish, Traditional Thai, and Chinese medicine to alleviate coughs, colds, and influenza symptoms. Early-stage laboratory studies indicate that this herbal extract may reduce inflammation and fever, and boost the body’s natural defenses against viruses, potentially leading to symptom relief. This review aims to systematically present clinical trial data about antiviral herbal formulations derived from Andrographis paniculata, delineating the antiviral effects of both natural and synthetic derivatives, along with in silico analyses.

show abstract

The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics

Cited by 3 publications

References 71 publications

Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial

Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial

Taiwan Chingguan Yihau may improve post-COVID-19 respiratory complications through PI3K/AKT, HIF-1, and TNF signaling pathways revealed by network pharmacology analysis

Antiviral efficacy of Andrographis paniculata and andrographolides: A narrative review

Contact Info

Product

Resources

About